Вход на сайт
Просмотр новости

Найдите то, что Вас интересует

No Difference in DFS Between Post-adjuvant Chemotherapy and Placebo In High-Risk Patients Identified Through ctDNA-based MRD Assessment After CRC Resection
Дата публикации: 22-06-2026 07:06:00




Основное содержимое страницы с новостью.

Subscribe to ESMO newsletter

Login to your ESMO Account to sign up for ESMO newsletters and receive information about ESMO's scientific and educational resources, events, member benefits.

ESMO is a Swiss-registered not-for-profit organisation. All funding for this site is provided directly by ESMO. Via Ginevra 4, 6900 Lugano - CH

© Copyright 2026 European Society for Medical Oncology All rights reserved worldwide.

Схожие новости

#Наименование новостиТональностьИнформативностьДата публикации
1Oral Sunvozertinib Prolongs PFS Over Chemotherapy as First-Line Treatment for Patients with Advanced NSCLC with EGFR Exon 20 Insertions0523-06-2026
2Blood test may help identify which colorectal cancer patients most likely to benefit from chemotherapy after surgery0506-07-2026
3Circulating Tumor DNA in Early Breast Cancer09.0201-07-2026
4Blood Test May Help Identify Which Colorectal Cancer Patients with Liver Metastases Are Most Likely to Benefit from Chemotherapy After Surgery0703-07-2026
5Addition of High-Dose Vitamin D 3 to Standard Treatment for Metastatic Colorectal Cancer013.4103-08-2026
6Pathologic Response After Neoadjuvant Chemoimmunotherapy in Head and Neck Squamous Cell Carcinoma04.4413-08-2026
7Hidden metastases reveal clues to colorectal cancer recurrence3709-07-2026
8Liquid Biopsies for Cancer08.3110-08-2026
9PFS in Metastatic Breast Cancer by Local Investigators vs Blinded Independent Central Review08.3416-07-2026
10Mezigdomide-Carfilzomib-Dexamethasone Prolongs PFS Compared with Carfilzomib-Dexamethasone at First Relapse in Patients with Relapsed Or Refractory Multiple Myeloma0509-07-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 5. Источник: www.esmo.org.